70 related articles for article (PubMed ID: 1380887)
21. [Relationship of an extracellular matrix protein, tenascin and breast diseases].
Ishihara A; Yatani R; Sakakura T
Rinsho Byori; 1993 Oct; 41(10):1099-107. PubMed ID: 7504753
[TBL] [Abstract][Full Text] [Related]
22. An expression study of hormone receptors in spontaneously developed, carcinogen-induced and hormone-induced mammary tumors in female Noble rats.
Cheung SY; Yuen MT; Choi HL; Cheng HK; Huang Y; Chen S; Chan FL
Int J Oncol; 2003 Jun; 22(6):1383-95. PubMed ID: 12739009
[TBL] [Abstract][Full Text] [Related]
23. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue.
Lightner VA; Marks JR; McCachren SS
Exp Cell Res; 1994 Feb; 210(2):177-84. PubMed ID: 7507849
[TBL] [Abstract][Full Text] [Related]
24. Independent regulation of growth and steroid receptors in uterus and mammary tumors of rats.
Janssens JP; Billiet G; Bonte J; De Loecker W
Anticancer Res; 1983; 3(6):385-91. PubMed ID: 6230984
[TBL] [Abstract][Full Text] [Related]
25. Effects of alterations in early hormonal environment on development and hormone dependency of carcinogen-induced mammary tumors in rats.
Sylvester PW; Aylsworth CF; Van Vugt DA; Meites J
Cancer Res; 1983 Nov; 43(11):5342-6. PubMed ID: 6413057
[TBL] [Abstract][Full Text] [Related]
26. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms.
Hauptmann S; Zardi L; Siri A; Carnemolla B; Borsi L; Castellucci M; Klosterhalfen B; Hartung P; Weis J; Stöcker G
Lab Invest; 1995 Aug; 73(2):172-82. PubMed ID: 7543628
[TBL] [Abstract][Full Text] [Related]
27. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
28. Effects of tamoxifen on mammary tumors and bone in 7,12-dimethylbenz-(a)anthracene-treated rats.
Suzuki S; Kitamura S; Sakamoto S; Sassa S; Mitamura T; Kudo H; Kuwa K; Yoshimura S; Maemura M; Nakayama T; Zhou YF; Hara Y; Shinoda H; Nagasawa H
Anticancer Res; 1998; 18(2A):871-6. PubMed ID: 9615734
[TBL] [Abstract][Full Text] [Related]
29. Tenascin in pregnant and non-pregnant rat uterus: unique spatio-temporal expression during decidualization.
Michie HJ; Head JR
Biol Reprod; 1994 Jun; 50(6):1277-86. PubMed ID: 7521676
[TBL] [Abstract][Full Text] [Related]
30. Altered tenascin expression during spontaneous endometrial carcinogenesis in the BDII/Han rat.
Vollmer G; Deerberg F; Siegal GP; Knuppen R
Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 60(2):83-9. PubMed ID: 1710855
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models.
Schneider MR; Michna H; Nishino Y; el Etreby MF
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):783-7. PubMed ID: 2285591
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone.
Nishino T; Ishibashi K; Hirtreiter C; Nishino Y
J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):187-90. PubMed ID: 19500671
[TBL] [Abstract][Full Text] [Related]
35. Mammary epithelial cell differentiation in vitro is regulated by an interplay of EGF action and tenascin-C downregulation.
Wirl G; Hermann M; Ekblom P; Fässler R
J Cell Sci; 1995 Jun; 108 ( Pt 6)():2445-56. PubMed ID: 7545689
[TBL] [Abstract][Full Text] [Related]
36. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma.
Ibrahim SN; Lightner VA; Ventimiglia JB; Ibrahim GK; Walther PJ; Bigner DD; Humphrey PA
Hum Pathol; 1993 Sep; 24(9):982-9. PubMed ID: 7504654
[TBL] [Abstract][Full Text] [Related]
37. The antitumor potency of progesterone antagonists is due to their differentiation potential.
Michna H; Gehring S; Kühnel W; Nishino Y; Schneider MR
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):203-10. PubMed ID: 1525061
[TBL] [Abstract][Full Text] [Related]
38. Tenascin immunoreactivity in lung tumors.
Soini Y; Pääkkö P; Nuorva K; Kamel D; Linnala A; Virtanen I; Lehto VP
Am J Clin Pathol; 1993 Aug; 100(2):145-50. PubMed ID: 7689293
[TBL] [Abstract][Full Text] [Related]
39. Appearance and distribution of stromal myofibroblasts and tenascin-C in feline mammary tumors.
Yoshimura H; Michishita M; Ohkusu-Tsukada K; Takahashi K
Histol Histopathol; 2011 Mar; 26(3):297-305. PubMed ID: 21210342
[TBL] [Abstract][Full Text] [Related]
40. Progesterone antagonists: tumor-inhibiting potential and mechanism of action.
Michna H; Nishino Y; Neef G; McGuire WL; Schneider MR
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):339-48. PubMed ID: 1562510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
